<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707105</url>
  </required_header>
  <id_info>
    <org_study_id>I2018001098</org_study_id>
    <nct_id>NCT04707105</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Study of Intracerebral Hemorrhage</brief_title>
  <acronym>POSTER</acronym>
  <official_title>A Prospective Observational Cohort Study in Chinese Patients With Primary Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators design a prospective, observational cohort study to provide contemporary&#xD;
      information on the prevalence, characteristics, risk stratification，cost-effective&#xD;
      ,treatments and prognosis of Chinese hospitalised adult patients with intracerebral&#xD;
      hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracerebral hemorrhage (ICH) remains a devastating disease with high mortality, yet few&#xD;
      therapeutic managements have been proved effective. Large quantities of work needs to be done&#xD;
      to fully delineate the prevalence and prognosis of ICH. Hence, the investigators design a&#xD;
      prospective, observational cohort study to provide contemporary information on the&#xD;
      prevalence, characteristics, risk stratification，cost-effective, treatments and prognosis of&#xD;
      Chinese hospitalised adult patients with ICH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with a 3-month modified Rankin Scale (mRS) score≤ 3</measure>
    <time_frame>2-3years</time_frame>
    <description>mRS 0-6, higher indicate worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute peripheral hematoma edema(PHE) growth</measure>
    <time_frame>2-3years</time_frame>
    <description>absolute peripheral hematoma edema growth in CT/MRI measured by picture archiving and communication systems(PACS) system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative peripheral hematoma edema(rPHE)</measure>
    <time_frame>2-3years</time_frame>
    <description>rPHE：absolute PHE divided by hematoma volume in CT/MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National institute of health stroke scale（NIHSS score）</measure>
    <time_frame>2-3years</time_frame>
    <description>NIHSS 0-42, higher indicate worse outcome</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">856</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Second Affiliated Hospital, School of Medicine, Zhejiang University</arm_group_label>
    <description>a prospective cohort of patients of primary intracerebral hemorrhage in Second Affiliated Hospital, School of Medicine, Zhejiang University</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second People's Hospital of Hangzhou City, Zhejiang Province</arm_group_label>
    <description>a prospective cohort of patients of primary intracerebral hemorrhage in Second People's Hospital of Hangzhou City, Zhejiang Province</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4th Affiliated Hospital, School of Medicine at Zhejiang University</arm_group_label>
    <description>a prospective cohort of patients of primary intracerebral hemorrhage in 4th Affiliated Hospital, School of Medicine at Zhejiang University</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        856 hospitalized patients over 18 years old with primary intrcerebral hemorrhage will be&#xD;
        enrolled consecutively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients over 18 years old of primary intracerebral hemorrhage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients of secondary intracerebral hemorrhage，such as hemorrhagic transformation of&#xD;
             ischemic stroke, aneurysmal, cavernomas, arterio- venous malformations, central venous&#xD;
             thrombosis, trauma-related, or tumor.&#xD;
&#xD;
          2. isolated intraventricular hemorrhage or subarachnoid hemorrhage pregnant patients；&#xD;
&#xD;
          3. surgical evacuation of hematoma；&#xD;
&#xD;
          4. unavailability to get complete blood cell samples and presenting contraindications or&#xD;
             refusal to MRI&#xD;
&#xD;
          5. patients cannot be followed up for any reasons.&#xD;
&#xD;
          6. patients death in 24 hours&#xD;
&#xD;
          7. pregnant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Gao, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Gao, MD,PhD</last_name>
    <phone>13588451471</phone>
    <email>2202012@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lusha Tong, MD,PhD</last_name>
    <phone>15868171218</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine at Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Gao, MD,PhD</last_name>
      <phone>13588451471</phone>
      <email>2202012@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary intracerebral hemorrhage</keyword>
  <keyword>hypertension</keyword>
  <keyword>perihematomal edema</keyword>
  <keyword>secondary brain injury</keyword>
  <keyword>remote diffusion-weighted imaging lesions (R-DWILs)</keyword>
  <keyword>immune response</keyword>
  <keyword>multimodel image</keyword>
  <keyword>cohort</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

